Omnimoxa (Moxifloxacin Hydrochloride)

Omnimoxa is a fluoroquinolone antibiotic that targets bacterial pathogens in ocular tissues.

• Bacterial conjunctivitis: Reduces bacterial load and accelerates healing of the conjunctiva.
• Bacterial keratitis: Eliminates pathogenic bacteria to prevent corneal damage and preserve vision.
• Post‑surgical prophylaxis: Helps prevent infection after eye surgery such as cataract extraction.

• Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription and repair. By blocking these enzymes, the drug prevents bacterial cell division and leads to bacterial cell death, providing a bactericidal effect against a broad spectrum of Gram‑positive and Gram‑negative organisms.

Adverse reactions to Omnimoxa are generally mild and related to local ocular irritation.

Common Side Effects

• Eye irritation: Stinging or burning sensation upon instillation.
• Redness: Conjunctival hyperemia.
• Tearing: Increased lacrimation.
• Foreign‑body sensation: Feeling of grit in the eye.
• Blurred vision: Temporary visual disturbance after dosing.

Serious or Rare Side Effects

• Corneal ulceration: Development of a corneal lesion.
• Anaphylaxis: Severe allergic reaction with systemic symptoms.
• Stevens‑Johnson syndrome: Rare mucocutaneous disorder.
• Toxic keratopathy: Damage to corneal epithelium.
• Vision loss: Sudden decrease in visual acuity.

When using Omnimoxa, consider the following safety measures:

• Contraindication: Do not use in patients with known hypersensitivity to moxifloxacin or other fluoroquinolones.
• Caution in corneal disease: Use carefully in patients with compromised corneal epithelium.
• Monitor pediatric use: Adjust monitoring for children as safety data are limited.
• Avoid contact lens wear: Discontinue lenses before and after instillation to prevent drug absorption.
• Store below 25°C: Keep in the original container, protect from light and moisture.

Omnimoxa may interact with other ophthalmic preparations and systemic medications.

Major Interactions (Avoid)

• Anticholinergic eye drops: May reduce ocular absorption of moxifloxacin.
• Corneal anesthetics: Increased risk of corneal toxicity when combined.

Moderate Interactions (Monitor Closely)

• Systemic fluoroquinolones: Additive risk of tendon toxicity.
• Non‑steroidal anti‑inflammatory eye drops: May enhance local irritation.
• Corticosteroid eye drops: Potential for delayed wound healing.